Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about JAZZ, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Cannabidiol FDA approved Jun 2018 · Epidiolex |
Dravet Syndrome (DS) | Phase 4 · NCT06924827 | Not yet recruiting |
| Lurbinectedin FDA approved Jun 2020 · Zepzelca |
Small-Cell Lung Cancer | Phase 3 · NCT05091567 | Active not recruiting |
| Zanidatamab (ZW25) FDA approved Nov 2024 · Ziihera |
Biliary Tract Cancer | Phase 3 · NCT06282575 | Recruiting |
| Asparaginase Erwinia chrysanthemi FDA approved Jun 2021 · Rylaze |
B Acute Lymphoblastic Leukemia, Philadelphia Chrom | Phase 2 · NCT06738368 | Suspended |
| Defibrotide FDA approved Mar 2016 · Defitelio |
Covid19 | Phase 2 · NCT04652115 | Recruiting |
| JZP258 (XYWAV) | Idiopathic Hypersomnia | Phase 4 · NCT05875974 | Completed |
| Fludarabine | Acute Myeloid Leukaemia | Phase 2/3 · NCT04217278 | Active not recruiting |
| JZP926 capsule | Juvenile Myoclonic Epilepsy | Phase 2/3 · NCT07723963 | Not yet recruiting |
| Dordaviprone (ONC201) | Diffuse Intrinsic Pontine Glioma | Phase 3 · NCT05476939 | Recruiting |
| Fluorouracil | Gastric Neoplasms | Phase 3 · NCT05152147 | Active not recruiting |
| Busulfan | Acute Myeloid Leukaemia | Phase 2/3 · NCT04217278 | Active not recruiting |
| CBD-OS | Developmental and Epileptic Encephalopathy (DEE) | Phase 3 · NCT07723976 | Not yet recruiting |
| Calcium, Magnesium, Potassium, And Sodiu | Narcolepsy | Phase 3 · NCT07625280 | Recruiting |
| (Daunorubicin And Cytarabine) Liposome | Acute Myeloid Leukaemia | Phase 2/3 · NCT04217278 | Active not recruiting |
| MicroRNA-10b Antagomir-Iron Oxide/Dextra | HER2-positive Breast Cancer | Phase 1/2 · NCT05868226 | Recruiting |
| Evorpacept (ALX148) | HER2-positive Breast Cancer | Phase 1/2 · NCT05868226 | Recruiting |
Also used in these trials (approved or third-party drugs, not JAZZ's own candidates): Trastuzumab, Etoposide, Tislelizumab, Durvalumab, Thiotepa, Everolimus, Gemcitabine Hydrochloride, Pembrolizumab, Oxaliplatin, Carboplatin, Atezolizumab, Capecitabine.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
JAZZ holds $2.2B in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when JAZZ files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Blackrock Inc. | Institution (13F) | 5,968,603 | 9.19% | 2026-06-30 |
| FMR LLC | Institution (13G, 5%+) | 4,675,459 | 7.20% | 2026-06-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 3,103,522 | 4.78% | 2026-03-31 |
| Vanguard Portfolio Management LLC | Institution (13F) | 3,036,213 | 4.68% | 2026-06-30 |
| Capital World Investors | Institution (13F) | 2,697,610 | 4.16% | 2026-06-30 |
| LSV Asset Management | Institution (13F) | 2,275,145 | 3.50% | 2026-06-30 |
| Franklin Resources, Inc. | Institution (13F) | 2,040,250 | 3.14% | 2026-06-30 |
| State Street Corporation | Institution (13F) | 1,999,816 | 3.08% | 2026-06-30 |
| Dimensional Fund Advisors LP | Institution (13F) | 1,713,592 | 2.64% | 2026-06-30 |
| Fuller & Thaler Asset Management Inc. | Institution (13F) | 1,638,544 | 2.52% | 2026-06-30 |
| Seamus Mulligan Director |
Insider | 1,286,254 | 1.98% | 2026-08-05 |
| Bruce C Cozadd Director |
Insider | 351,875 | 0.54% | 2026-08-31 |
Share count 64,914,577 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-09-10 filed 2026-09-14 |
Patil Neena M |
Sale (S) | 1,200 | $240.94 | 47,671 |
| 2026-09-08 filed 2026-09-10 |
Henderson Mary Elizabeth |
Tax withholding (F) | 15 | $241.20 | 23,815 |
| 2026-09-08 filed 2026-09-10 |
Henderson Mary Elizabeth |
Tax withholding (F) | 1,412 | $243.03 | 23,830 |
| 2026-09-08 filed 2026-09-10 |
GALA RENEE D |
Sale (S) | 2,000 | $243.03 | 143,394 |
| 2026-09-08 filed 2026-09-10 |
GALA RENEE D |
Tax withholding (F) | 1,967 | $246.81 | 145,394 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-08-25 | Ziihera | sBLA | +0.2% | +2.3% | — |
| 2025-11-05 | — | NDA | +0.2% | -0.4% | -0.5% |
| 2025-10-07 | — | NDA | +6.2% | -0.2% | -1.8% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for JAZZ and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →